Newer agents for the treatment of painful diabetic peripheral neuropathy

Current Diabetes Reports

Volumn 5, Issue 6, 2005, Pages 409-416

  Freeman, Roy ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; ETIRACETAM; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; MILNACIPRAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; PHENYTOIN; PREGABALIN; SODIUM CHANNEL BLOCKING AGENT; TOPICAL AGENT; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZONISAMIDE;

ANALGESIC ACTIVITY; ANOREXIA; ATAXIA; BODY WEIGHT DISORDER; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DYSPEPSIA; ERYTHEMA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; HYPONATREMIA; INSOMNIA; IRRITABILITY; MORBIDITY; NAUSEA; NERVE INJURY; NERVOUS SYSTEM FUNCTION; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN BURNING SENSATION; SNEEZING; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SWEATING; TREATMENT PLANNING; TREMOR; VISUAL DISORDER; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANALGESICS; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DIABETIC NEUROPATHIES; HUMANS; PAIN; TREATMENT OUTCOME;

EID: 29644438075     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0047-7     Document Type: Review

References (98)

1. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Ziegler D, Gries FA, Spuler M, Lessmann F: The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992, 6:49-57.
3. Schmader KE: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350-354.
4. Partanen J, Niskanen L, Lehtinen J, et al.: Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:89-94.
5. Galer BS, Gianas A, Jensen MP: Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123-128.
6. Basbaum AI, Jessell TM: The perception of pain. In Principles of Neural Science, edn 4. Edited by Kandel ER, et al. New York: McGraw-Hill; 2000:472-491.
7. Woolf CJ, Mannion RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353:1959-1964.
8. Max MB, Culnane M, Schafer SC, et al.: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987, 37:589-596.
9. Max MB, Kishore-Kumar R, Schafer SC, et al.: Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991, 45:3-9.
10. Max MB, Lynch SA, Muir J, et al.: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326:1250-1256.
11. Sindrup SH, Jensen TS: Pharmacologic treatment of pain in polyneuropathy. Neurology 2000, 55:915-920.
12. Sindrup SH, Gram LF, Skjold T, et al.: Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990, 30:683-691.
13. Jackson WK, Roose SP, Glassman AH: Cardiovascular toxicity of antidepressant medications. Psychopathology 1987, 20(suppl 1):64-74.
14. Glassman AH, Roose SP, Bigger JT Jr: The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993, 269:2673-2675.
15. Roose SP, Glassman AH, Dalack GW: Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry 1989, 50(suppl):12-16.
16. Cohen HW, Gibson G, Alderman MH: Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000, 108:2-8.
17. Roose SP, Laghrissi-Thode F, Kennedy JS, et al.: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998, 279:287-291.
18. Sindrup SH, Bjerre U, Dejgaard A, et al.: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992, 52:547-552.
19. Sindrup SH, Gram LF, Brosen K, et al.: The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990, 42:135-144.
20. Semenchuk MR, Sherman S, Davis B: Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001, 57:1583-1588.
21. Lang E, Hord AH, Denson D: Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain 1996, 68:151-155.
22. Schreiber S, Backer MM, Pick CG: The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999, 273:85-88.
23. Sindrup SH, Bach FW, Madsen C, et al.: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003, 60:1284-1289.
24. Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004, 110:697-706.
25. Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000, 57:503-509.
26. Vaishnavi SN, Nemeroff CB, Plott SJ, et al.: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004, 55:320-322.
27. Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998, 349:129-132.
28. Iyengar S, Webster AA, Hemrick-Luecke SK, et al.: Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004, 311:576-584.
29. Jones CK, Peters SC, Shannon HE: Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005, 312:726-732.
30. Goldstein DJ, Lu Y, Detke MJ, et al.: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004, 45:17-28.
31. Goldstein DJ, Lu Y, Detke MJ, et al.: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005, 116:109-118.
32. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano CO: Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double-blind crossover trial. Diabetologia 1969, 5:215-218.
33. Saudek CD, Werns S, Reidenberg MM: Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 1977, 22:196-199.
34. Chadda VS, Mathur MS: Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 1978, 26:403-406.
35. Kochar DK, Rawat N, Agrawal RP, et al.: Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004, 97:33-38.
36. Kochar DK, Jain N, Agarwal RP, et al.: Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Acta Neurol Scand 2002, 106:248-252.
37. Otto M, Bach FW, Jensen TS, Sindrup SH: Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology 2004, 62:285-288.
38. Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831-1836.
39. Gorson KC, Schott C, Herman R, et al.: Gabapentin in the treatment of painful diabetic neuropathy: a placebo-controlled, double-blind, crossover trial. J Neurol Neurosurg Psychiatry 1999, 66:251-252.
40. Backonja M, Glanzman RL: Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003, 25:81-104.
41. Morello CM, Leckband SG, Stoner CP, et al.: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999, 159:1931-1937.
42. Sabatowski R, Galvez R, Cherry DA, et al.: Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004, 109:26-35.
43. Dworkin RH, Corbin AE, Young JP Jr, et al.: Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003, 60:1274-1283.
44. Richter RW, Portenoy R, Sharma U, et al.: Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005, 6:253-260.
45. Lesser H, Sharma U, LaMoreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004, 63:2104-2110.
46. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628-638.
47. Freynhagen R, Strojek K, Griesing T, et al.: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005, 115:254-263.
48. McLean MJ: Gabapentin. Epilepsia 1995, 36(suppl 2):S73-S86.
49. Gee NS, Brown JP, Dissanayake VU, et al.: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996, 271:5768-5776.
50. Field MJ, Hughes J, Singh L: Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. Br J Pharmacol 2000, 131:282-286.
51. Taylor CP, Gee NS, Su TZ, et al.: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998, 29:233-249.
52. Fehrenbacher JC, Taylor CP, Vasko MR: Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003, 105:133-141.
53. Dooley DJ, Mieske CA, Borosky SA: Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000, 280:107-110.
54. Fink K, Dooley DJ, Meder WP, et al.: Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002, 42:229-236.
55. Fink K, Meder W, Dooley DJ, Gothert M: Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000, 130:900-906.
56. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ: Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002, 45:171-190.
57. Barber LA, Vasko MR: Activation of protein kinase C augments peptide release from rat sensory neurons. J Neurochem 1996, 67:72-80.
58. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41(suppl 1):S3-S9.
59. Thienel U, Neto W, Schwabe SK, Vijapurkar U: Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004, 110:221-231.
60. Raskin P, Donofrio PD, Rosenthal NR, et al.: Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004, 63:865-873.
61. Dodgson SJ, Shank RP, Maryanoff BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000, 41(suppl 1):S35-S39.
62. Cheung H, Kamp D, Harris E: An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992, 13:107-112.
63. Eisenberg E, Lurie Y, Braker C, et al.: Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001, 57:505-509.
64. Simpson DM, Olney R, McArthur JC, et al.: A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000, 54:2115-2119.
65. Simpson DM, McArthur JC, Olney R, et al.: Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003, 60:1508-1514.
66. Vestergaard K, Andersen G, Gottrup H, et al.: Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001, 56:184-190.
67. Finnerup NB, Sindrup SH, Bach FW, et al.: Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002, 96:375-383.
68. Beydoun A, Kobetz SA, Carrazana EJ: Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain 2004, 20:174-178.
69. Wamil AW, Schmutz M, Portet C, et al.: Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994, 271:301-308.
70. McLean MJ, Schmutz M, Wamil AW, et al.: Oxcarbazepine: mechanisms of action. Epilepsia 1994, 35(suppl 3):S5-S9.
71. Stracke H, Meyer UE, Schumacher HE, Federlin K: Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992, 15:1550-1555.
72. Oskarsson P, Ljunggren JG, Lins PE: Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997, 20:1594-1597.
73. Dejgard A, Petersen P, Kastrup J: Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988, 1:9-11.
74. Wright JM, Oki JC, Graves L: Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997, 31:29-34.
75. Jarvis B, Coukell AJ: Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998, 56:691-707.
76. Kieburtz K, Simpson D, Yiannoutsos C, et al.: A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998, 51:1682-1688.
77. Simone DA, Nolano M, Johnson T, et al.: Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 1998, 18:8947-8959.
78. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group [no authors listed]. Arch Intern Med 1991, 151:2225-2229.
79. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group [no authors listed]. Diabetes Care 1992, 15:159-165.
80. Bernstein JE, Korman NJ, Bickers DR, et al.: Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989, 21:265-270.
81. Biesbroeck R, Bril V, Hollander P, et al.: A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 1995, 12:111-120.
82. Tandan R, Lewis GA, Badger GB, Fries TJ: Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care 1992, 15:15-18.
83. Watson CP, Evans RJ, Watt VR: Post-herpetic neuralgia and topical capsaicin. Pain 1988, 33:333-340.
84. Watson CP, Tyler KL, Bickers DR, et al.: A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993, 15:510-526.
85. Galer BS, Rowbotham MC, Perander J, Friedman E: Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999, 80:533-538.
86. Rowbotham MC, Davies PS, Fields HL: Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995, 37:246-253.
87. Rowbotham MC, Davies PS, Verkempinck C, Galer BS: Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996, 65:39-44.
88. Barbano RL, Herrmann DN, Hart-Gouleau S, et al.: Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004, 61:914-918.
89. Harati Y, Gooch C, Swenson M, et al.: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50:1842-1846.
90. Sindrup SH, Andersen G, Madsen C, et al.: Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999, 83:85-90.
91. Cohen KL, Lucibello FE, Chomiak M: Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care 1990, 13:1074-1077.
92. Harati Y, Gooch C, Swenson M, et al.: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50:1842-1846.
93. Sindrup SH, Madsen C, Brosen K, Jensen TS: The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999, 66:636-641.
94. Raffa RB, Friderichs E, Reimann W, et al.: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992, 260:275-285.
95. Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003, 60:927-934.
96. Watson CP, Moulin D, Watt-Watson J, et al.: Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003, 105:71-78.
97. Nelson KA, Park KM, Robinovitz E, et al.: High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997, 48:1212-1218.
98. Sang CN, Booher S, Gilron I, et al.: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002, 96:1053-1061.